Key result
Moderate-intensity statins in CAD with LDL-C 70-/dL prove cost-effective at ~$20,000 per QALY gained.
Answers are grounded in this paper and cite their sources.
BACKGROUND: The recommended target low-density lipoprotein cholesterol (LDL-C) level for coronary artery disease (CAD) patients has been lowered from 100 to 70 mg/dL in several clinical guidelines for secondary prevention. We aimed to assess whether initiating statin treatment in CAD patients with baseline LDL-C 70-100 mg/dL in Taiwan could be cost-effective. METHODS: A Markov model was developed to simulate a hypothetical cohort of CAD patients with a baseline LDL-C level of 90 mg/dL. The incidence and recurrence of MI and stroke related to specific LDL-C levels as well as the statin effect, mortality rate, and health state utilities were obtained from the literature. The direct medical costs and rate of fatal events were derived from the national claims database. The incremental cost-effectiveness ratio (ICER) per quality-adjusted life years (QALYs) was calculated, and sensitivity analyses were performed. RESULTS: Moderate-intensity statin use, a treatment regimen expected to achieve LDL <70 mg/dL in the base case, resulted in a net gain of 562 QALYs but with an additional expenditure of $11.4 million per 10,000 patients over ten years. The ICER was $20,288 per QALY gained. The probabilities of being cost-effective at willingness-to-pay thresholds of one and three gross domestic product per capita ($24,329 in 2017) per QALY were 51.1% and 94.2%, respectively. Annual drug cost was the most influential factor on the ICER. CONCLUSION: Lowering the target LDL-C level from 100 to 70 mg/dL among treatment-naïve CAD patients could be cost-effective given the health benefits of preventing cardiovascular events and deaths.
No takes yet. Share an insight, caveat, or question.
Lin et al. (2020) studied Coronary artery disease with baseline LDL-C 70-100 mg/dL (n=10,000). Moderate-intensity statin therapy (target LDL-C <70 mg/dL) vs. No statin treatment (target LDL-C <100 mg/dL) was evaluated on Incremental cost-effectiveness ratio (ICER) per quality-adjusted life year (QALY) gained (ICER $20,288/QALY). Moderate-intensity statin therapy in CAD patients with LDL-C 70-/dL gained 562 QALYs per 10,000 patients over 10 years with an ICER of $20,288 per QALY gained.
Synapse has enriched 10 related papers. Consider them for comparative context: